PD-L1 Expression and Its Clinical Relevance in Neuroendocrine Tumors of the Lung Abstract #2198

Introduction: Immune checkpoint regulation seems to be crucial for nonneuroendocrine lung cancer patients. However, little is known in lung neuroendocrine tumors.
Aim(s): We aimed to clarify PD-L1 expression status and its prognostic significance in lung neuroendocrine tumors.
Materials and methods: Tumor-associated inflammation was evaluated in 57 resected carcinoids and in 185 resected neuroendocrine carcinomas (NECs) of the lung (58 large cell and 127 small cell type). Immunohistochemical PD-L1 (clone 22C3) expression was separately assessed in immune cells (IC) and tumor cells (TC). CD8 and CD68 were evaluated in representative cases. All data were correlated with follow up.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Atsuko Kasajima
Keywords: Lung NEN, PD-L1, Prognosis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1668 Classification of Lung Neuroendocrine Neoplasms (Lung-NENs) According to WHO 2010 for Gastroenteropancreatic NENs (GEP-NENs) Has Prognostic Relevance and Includes Lung-NETs G3
Introduction: The classification of lung neuroendocrine neoplasms (Lung-NENs) according to the WHO classification 2010 for GEP-NENs, including a provisional category for Lung-NET G3 with Ki67 >20%, may have prognostic implications.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
Authors: Kasajima A, Oka N, Ishida H, Sakurada A, ...
Keywords: Lung NEN
#2793 A Phase II, Open-Label, Multicenter Trial of Avelumab in Patients with Advanced, Metastatic High Grade Neuroendocrine Carcinomas NEC G3 (WHO 2010) Progressive after First-line Chemotherapy (AVENEC)
Introduction: High grade Neuroendocrine Neoplasias (NEN) are rare tumors with a poor prognosis and no established second line therapy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: PD. Dr. Christian Fottner
#2991 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasia G3 (NEN G3) According to 2019 WHO Classification: A Comprehensive Clinicopathological Characterization Including Mismatch Repair (MMR) Proteins, PDL1 Expression and KRAS/BRAF Status
Introduction: In the 2019 WHO FOR NEN’S classification NETG3 have been distinguished from poorly differentiated neuroendocrine carcinoma (NEC). They are heterogeneous group concerning prognosis and treatment benefit.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD Gonzalo Ruiz
Keywords: G3 NEN, PD-L1, KRAS, BIOMARKERS
#1630 The Positive Expression of PD-L1/PD-1 in Gastroenteropancreatic Neuroendocrine Neoplasias Correlates with Prognosis
Introduction: The incidence of Neuroendocrine Neoplasias (NENs) is increasing and their pathological characteristics, varied between races. However, the epidemiology of GEP-NENs in Chinese patients remains poorly characterized especially for the expression of important immune checkpoint protein PD1 and PD-L1.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Pathology, grading, staging
Presenting Author: Wu Yinying
Authors: Yinying W, Chuying W, ...
#1672 PD-L1 Expression and Quantitative Assessment of Tumor-Infiltrating T Cell Subsets in Carcinoid Tumors and Large Cell Neuroendocrine Carcinomas of the Lung
Introduction: Little is known about the expression of PD-L1 an the immune infiltrate in neuroendocrine neoplasms of the lung.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Biomarkers
Presenting Author: Dr Julien Hadoux